61
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Pol II phosphorylation regulates a switch between transcriptional and splicing condensates

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The synthesis of pre-mRNA by RNA polymerase II (Pol II) involves the formation of a transcription initiation complex and a transition to an elongation complex 14 . The large subunit of Pol II contains an intrinsically disordered C-terminal domain (CTD), which is phosphorylated by cyclin-dependent kinases (CDKs) during the initiation-to-elongation transition, thus influencing the CTD’s interaction with different components of the initiation or the RNA splicing apparatus ( Fig. 1a) 5, 6 . Recent observations suggest that this model provides only a partial picture of the effects of CTD phosphorylation. Both the transcription initiation machinery and the splicing machinery can form phase-separated condensates containing large numbers of component molecules; hundreds of Pol II and Mediator molecules are concentrated in condensates at super-enhancers 7, 8 and large numbers of splicing factors are concentrated in nuclear speckles, some of which occur at highly active transcription sites 912 . Here we investigate whether phosphorylation of the CTD regulates its incorporation into phase-separated condensates associated with transcription initiation and splicing. We find that the hypophosphorylated Pol II CTD is incorporated into Mediator condensates and that phosphorylation by regulatory CDKs reduces this incorporation. We also find that the hyperphosphorylated CTD is preferentially incorporated into condensates formed by splicing factors. These results suggest that Pol II CTD phosphorylation drives an exchange from condensates involved in transcription initiation to those involved in RNA processing and implicates phosphorylation as a mechanism to regulate condensate preference.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          A general method to improve fluorophores for live-cell and single-molecule microscopy

          Specific labeling of biomolecules with bright fluorophores is the keystone of fluorescence microscopy. Genetically encoded self-labeling tag proteins can be coupled to synthetic dyes inside living cells, resulting in brighter reporters than fluorescent proteins. Intracellular labeling using these techniques requires cell-permeable fluorescent ligands, however, limiting utility to a small number of classic fluorophores. Here, we describe a simple structural modification that improves the brightness and photostability of dyes while preserving spectral properties and cell permeability. Inspired by molecular modeling, we replaced the N,N-dimethylamino substituents in tetramethylrhodamine with four-membered azetidine rings. This addition of two carbon atoms doubles the quantum efficiency and improves the photon yield of the dye in applications ranging from in vitro single-molecule measurements to super-resolution imaging. The novel substitution is generalizable, yielding a palette of chemical dyes with improved quantum efficiencies that spans the UV and visible range.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans.

            Recent years have witnessed a sea change in our understanding of transcription regulation: whereas traditional models focused solely on the events that brought RNA polymerase II (Pol II) to a gene promoter to initiate RNA synthesis, emerging evidence points to the pausing of Pol II during early elongation as a widespread regulatory mechanism in higher eukaryotes. Current data indicate that pausing is particularly enriched at genes in signal-responsive pathways. Here the evidence for pausing of Pol II from recent high-throughput studies will be discussed, as well as the potential interconnected functions of promoter-proximally paused Pol II.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The Mediator complex: a central integrator of transcription.

              The RNA polymerase II (Pol II) enzyme transcribes all protein-coding and most non-coding RNA genes and is globally regulated by Mediator - a large, conformationally flexible protein complex with a variable subunit composition (for example, a four-subunit cyclin-dependent kinase 8 module can reversibly associate with it). These biochemical characteristics are fundamentally important for Mediator's ability to control various processes that are important for transcription, including the organization of chromatin architecture and the regulation of Pol II pre-initiation, initiation, re-initiation, pausing and elongation. Although Mediator exists in all eukaryotes, a variety of Mediator functions seem to be specific to metazoans, which is indicative of more diverse regulatory requirements.
                Bookmark

                Author and article information

                Journal
                0410462
                6011
                Nature
                Nature
                Nature
                0028-0836
                1476-4687
                16 July 2019
                07 August 2019
                August 2019
                07 February 2020
                : 572
                : 7770
                : 543-548
                Affiliations
                [1 ]Whitehead Institute for Biomedical Research, 455 Main Street, Cambridge, MA 02142, USA
                [2 ]Department of Biology
                [3 ]Department of Physics
                [4 ]Department of Chemical Engineering
                [5 ]Institute of Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
                [6 ]Department of Biochemistry, University of Colorado, Boulder, CO 80303, USA
                [7 ]Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
                [8 ]Present address: Department of Physics, University of Illinois at Chicago, Chicago, IL 60607, USA
                [9 ]Present address: Computational Biology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
                [10 ]These authors contributed equally to this work
                Author notes

                Author contributions

                Y.E.G. and R.A.Y. conceived the project. Y.E.G., J.C.M., and R.A.Y. organized the studies and wrote the manuscript. Y.E.G. and B.R.S. performed in vitro droplet formation assays. J.C.M., A.D., and A.B. performed immunofluorescence experiments. J.E.H. and K.S. developed and performed computational analyses. B.R.S., Y.E.G, B.J.A. and J.C.M. performed ChIP/analyzed data. N.M.H. purified recombinant proteins. Y.E.G., J.E.H. and L.K.A. generated cell lines. J.H.S. and A.V.Z. performed lattice light-sheet microscopy and analysis. T-M.D., J.R., C.F. and D.T. purified human Mediator. Y.E.G., J.C.M. and J.E.H. generated constructs. J.E.H. performed live cell imaging. J.E.H. and T.I.L. contributed to writing the manuscript. P.A.S. and I.I.C. provided input into experimental design and interpretation. R.A.Y. supervised the project with the help from T.I.L. All authors contributed to editing the manuscript.

                Author information

                R.A.Y. is a founder and shareholder of Syros Pharmaceuticals, Camp4 Therapeutics, Omega Therapeutics and Dewpoint Therapeutics. P.A.S. is a member of the Board and shareholder in Syros and a member of the Scientific Advisory Board of Dewpoint. B.J.A. and T.I.L. are shareholders of Syros Pharmaceuticals. T.I.L. is a consultant to Camp4 Therapeutics and I.I.C. is a consultant to Dewpoint Therapeutics. All other authors declare no competing interests. Datasets generated in this study have been deposited in the Gene Expression Omnibus under accession number GSE120656.

                [* ]Correspondence to: Richard A. Young ( young@ 123456wi.mit.edu )
                Article
                NIHMS1534331
                10.1038/s41586-019-1464-0
                6706314
                31391587
                c754d629-6b85-46a1-8054-28265926fd2b

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article